RU97121883A - APPLICATION AT LEAST ONE β-ADRENERGIC AGONIST AS AN ANTAGONIST OF SUBSTANCE P - Google Patents
APPLICATION AT LEAST ONE β-ADRENERGIC AGONIST AS AN ANTAGONIST OF SUBSTANCE PInfo
- Publication number
- RU97121883A RU97121883A RU97121883/14A RU97121883A RU97121883A RU 97121883 A RU97121883 A RU 97121883A RU 97121883/14 A RU97121883/14 A RU 97121883/14A RU 97121883 A RU97121883 A RU 97121883A RU 97121883 A RU97121883 A RU 97121883A
- Authority
- RU
- Russia
- Prior art keywords
- adrenergic agonist
- composition
- intended
- use according
- skin
- Prior art date
Links
- 239000000808 adrenergic beta-agonist Substances 0.000 title claims 11
- 230000003042 antagnostic Effects 0.000 title claims 2
- 239000005557 antagonist Substances 0.000 title claims 2
- 239000000126 substance Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims 10
- 238000002360 preparation method Methods 0.000 claims 4
- ADNPLDHMAVUMIW-CUZNLEPHSA-N (2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-N-[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-y Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 claims 3
- 210000004400 Mucous Membrane Anatomy 0.000 claims 3
- 208000003251 Pruritus Diseases 0.000 claims 3
- 210000003491 Skin Anatomy 0.000 claims 3
- 102100002996 TAC1 Human genes 0.000 claims 3
- 101700065588 TAC1 Proteins 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010015150 Erythema Diseases 0.000 claims 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N Salbutamol Chemical group CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 2
- 208000006641 Skin Disease Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 239000002537 cosmetic Substances 0.000 claims 2
- 231100000321 erythema Toxicity 0.000 claims 2
- 230000000622 irritating Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000004681 psoriasis Diseases 0.000 claims 2
- 229960002052 salbutamol Drugs 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 230000035807 sensation Effects 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- 230000002194 synthesizing Effects 0.000 claims 2
- 230000000699 topical Effects 0.000 claims 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N 4-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}benzene-1,2-diol Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims 1
- 229940100197 ANTIMETABOLITES Drugs 0.000 claims 1
- RZVHIXYEVGDQDX-UHFFFAOYSA-N Anthraquinone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3C(=O)C2=C1 RZVHIXYEVGDQDX-UHFFFAOYSA-N 0.000 claims 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N Bricaril Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims 1
- UMQUQWCJKFOUGV-UHFFFAOYSA-N CGP 12177 Chemical compound CC(C)(C)NCC(O)COC1=CC=CC2=C1NC(=O)N2 UMQUQWCJKFOUGV-UHFFFAOYSA-N 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 208000010247 Contact Dermatitis Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- LSLYOANBFKQKPT-UHFFFAOYSA-N Fenoterol Chemical compound C=1C(O)=CC(O)=CC=1C(O)CNC(C)CC1=CC=C(O)C=C1 LSLYOANBFKQKPT-UHFFFAOYSA-N 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 229940039009 Isoproterenol Drugs 0.000 claims 1
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 claims 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 1
- 206010040880 Skin irritation Diseases 0.000 claims 1
- 206010040943 Skin ulcer Diseases 0.000 claims 1
- 229960000195 Terbutaline Drugs 0.000 claims 1
- 206010046736 Urticarias Diseases 0.000 claims 1
- 229940046008 Vitamin D Drugs 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 150000004716 alpha keto acids Chemical class 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 230000001166 anti-perspirant Effects 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000003213 antiperspirant Substances 0.000 claims 1
- 150000001277 beta hydroxy acids Chemical class 0.000 claims 1
- 150000004718 beta keto acids Chemical class 0.000 claims 1
- 229960005188 collagen Drugs 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000035614 depigmentation Effects 0.000 claims 1
- 231100000080 dermatitis contact Toxicity 0.000 claims 1
- 239000000975 dye Substances 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 229960001022 fenoterol Drugs 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 239000000118 hair dye Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 229960001317 isoprenaline Drugs 0.000 claims 1
- 229910003002 lithium salt Inorganic materials 0.000 claims 1
- 159000000002 lithium salts Chemical class 0.000 claims 1
- 230000035800 maturation Effects 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 150000002978 peroxides Chemical class 0.000 claims 1
- 229960005414 pirbuterol Drugs 0.000 claims 1
- 229960004017 salmeterol Drugs 0.000 claims 1
- 230000037307 sensitive skin Effects 0.000 claims 1
- 231100000475 skin irritation Toxicity 0.000 claims 1
- 230000036556 skin irritation Effects 0.000 claims 1
- 231100000019 skin ulcer Toxicity 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
Claims (15)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR95/12447 | 1995-10-23 | ||
FR9512447A FR2740040B1 (en) | 1995-10-23 | 1995-10-23 | USE OF AT LEAST ONE BETA-ADRENERGIC AGONIST AS A SUBSTANCE P ANTAGONIST |
Publications (2)
Publication Number | Publication Date |
---|---|
RU97121883A true RU97121883A (en) | 1999-09-27 |
RU2169552C2 RU2169552C2 (en) | 2001-06-27 |
Family
ID=9483809
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU97121883/14A RU2169552C2 (en) | 1995-10-23 | 1996-10-01 | Applying at least one beta-adrenergic agonist as substance b agonist |
Country Status (14)
Country | Link |
---|---|
US (2) | US5958432A (en) |
EP (1) | EP0769293B1 (en) |
JP (1) | JP3636473B2 (en) |
AR (1) | AR004052A1 (en) |
BR (1) | BR9611302A (en) |
CA (1) | CA2222311C (en) |
DE (1) | DE69603681T2 (en) |
DK (1) | DK0769293T3 (en) |
FR (1) | FR2740040B1 (en) |
HU (1) | HUP9900511A3 (en) |
NO (1) | NO312273B1 (en) |
PL (1) | PL186366B1 (en) |
RU (1) | RU2169552C2 (en) |
WO (1) | WO1997015281A1 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5948972A (en) * | 1994-12-22 | 1999-09-07 | Kla-Tencor Corporation | Dual stage instrument for scanning a specimen |
AU8298801A (en) | 2000-07-26 | 2002-02-05 | John K Vyden | Methods for treating atopic disorders |
ITPD20010187A1 (en) * | 2001-07-23 | 2003-01-23 | Cutech Srl | POLYPHERIC FOLLICLE TREATMENT, IN PARTICULAR AGAINST HAIR LOSS |
EP1295599A1 (en) * | 2001-09-21 | 2003-03-26 | Boehringer Ingelheim International GmbH | Method for the treatment of prevention of atopic dermatitis |
US20030219573A1 (en) * | 2002-03-27 | 2003-11-27 | Torgny Falk | Absorbent product |
US8343519B2 (en) * | 2003-02-19 | 2013-01-01 | L'oreal S.A. | Chemical enhancer and method |
EP1613266A4 (en) * | 2003-04-15 | 2009-05-06 | Theraquest Biosciences Llc | Methods of treating pain and compositions for use therefor |
JPWO2006054513A1 (en) * | 2004-11-19 | 2008-05-29 | キッセイ薬品工業株式会社 | Preventive or therapeutic agent for neuropathic pain |
EP1719507B1 (en) | 2005-04-13 | 2010-07-14 | Astion Development A/S | Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin |
WO2009112674A2 (en) * | 2008-01-18 | 2009-09-17 | Centre National De La Recherche Scientifique - Cnrs | Compounds for use in the treatment of neuropathic pain |
GB0805535D0 (en) | 2008-03-27 | 2008-04-30 | Univ Leicester | Scar prevention |
US8420114B2 (en) * | 2008-04-18 | 2013-04-16 | Warsaw Orthopedic, Inc. | Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation |
JP5425229B2 (en) * | 2009-02-24 | 2014-02-26 | ノバルティス アーゲー | Use of NK receptor antagonists |
GB2513297A (en) | 2013-03-08 | 2014-10-29 | Univ Leicester | Methods |
EP3319607A4 (en) * | 2015-07-09 | 2019-04-03 | Galderma S.A. | Method of reducing hair loss associated with chemotherapy |
JP7152051B2 (en) * | 2018-05-29 | 2022-10-12 | 株式会社ナノエッグ | Composition for treating or preventing atopic dermatitis |
AU2019336248A1 (en) * | 2018-09-08 | 2021-05-13 | Tan WEN | New use of R-enantiomer of adrenergic β2 receptor agonists for treatment of inflammatory bowel disease and its extra intestinal manifestations |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1474316A (en) * | 1975-02-12 | 1977-05-25 | Seperic | O-aminoalkyl oximes |
US4038417A (en) * | 1975-06-19 | 1977-07-26 | Nelson Research & Development Company | Method for treatment of psoriasis |
US4525359A (en) * | 1982-12-10 | 1985-06-25 | Greenway Frank L Iii | Treatment for selective weight control |
US5366731A (en) * | 1990-08-24 | 1994-11-22 | Wisconsin Alumni Research Foundation | Cosmetic compositions containing secosterol compounds |
IL99368A (en) * | 1991-09-02 | 1996-01-19 | Teva Pharma | Compositions for topical treatment of psoriasis and atopic dermatitis comprising a xanthine derivative |
CA2114968A1 (en) * | 1993-02-25 | 1994-08-26 | John Wille | Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity |
JPH07258067A (en) * | 1994-03-18 | 1995-10-09 | Kao Corp | Bathing agent composition |
FR2719474B1 (en) * | 1994-05-05 | 1996-05-31 | Oreal | Use of a substance P antagonist in a cosmetic composition and composition obtained. |
-
1995
- 1995-10-23 FR FR9512447A patent/FR2740040B1/en not_active Expired - Fee Related
-
1996
- 1996-10-01 EP EP96402098A patent/EP0769293B1/en not_active Expired - Lifetime
- 1996-10-01 CA CA002222311A patent/CA2222311C/en not_active Expired - Fee Related
- 1996-10-01 RU RU97121883/14A patent/RU2169552C2/en not_active IP Right Cessation
- 1996-10-01 DE DE69603681T patent/DE69603681T2/en not_active Expired - Fee Related
- 1996-10-01 DK DK96402098T patent/DK0769293T3/en active
- 1996-10-01 PL PL96324924A patent/PL186366B1/en not_active IP Right Cessation
- 1996-10-01 HU HU9900511A patent/HUP9900511A3/en unknown
- 1996-10-01 JP JP51633197A patent/JP3636473B2/en not_active Expired - Fee Related
- 1996-10-01 BR BR9611302A patent/BR9611302A/en not_active IP Right Cessation
- 1996-10-01 WO PCT/FR1996/001530 patent/WO1997015281A1/en active Application Filing
- 1996-10-21 AR ARP960104829A patent/AR004052A1/en not_active Application Discontinuation
- 1996-10-23 US US08/731,967 patent/US5958432A/en not_active Expired - Fee Related
-
1997
- 1997-12-30 NO NO19976143A patent/NO312273B1/en unknown
-
1999
- 1999-05-12 US US09/310,099 patent/US6267972B1/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU97121883A (en) | APPLICATION AT LEAST ONE β-ADRENERGIC AGONIST AS AN ANTAGONIST OF SUBSTANCE P | |
JP3112436B2 (en) | In particular, the use of honey as a keratolytic agent to improve the brightness of the skin facial and treat wrinkles | |
US6248763B1 (en) | Composition for treating skin conditions | |
AU721214B2 (en) | Composition and method for effecting superficial chemical skin peels | |
JP2004196828A (en) | Composition for treating hypersensitive skin | |
US20040102358A1 (en) | Composition for treating skin conditions | |
KR100264829B1 (en) | Treatment of acne or of pseud of olliculitis barbae. | |
MXPA97005954A (en) | Formulations and methods to reduce irritation of the p | |
JPH10513452A (en) | Formulations and methods for reducing skin irritation | |
US20070134175A1 (en) | Panthenol and natural organic extracts for reducing skin irritation | |
RU96101808A (en) | AGENT FOR PROCESSING SENSITIVE SKIN, COMPOSITION ON ITS BASIS AND METHOD FOR PROCESSING SKIN | |
JP2005519126A5 (en) | ||
WO2002030367A3 (en) | Scalp cosmetic and dermatological compositions | |
JPH11501941A (en) | Topical composition containing capsazepine | |
RU97121886A (en) | APPLICATION OF THE EXTRACT AS A LESS THAN ONE SINGLE-COLORED PLANT IN A COMPOSITION | |
US5221533A (en) | Skin lotion composition | |
JP3636473B2 (en) | Use of at least one beta-adrenergic agonist as a substance P antagonist | |
JP2002536069A (en) | Method and composition for reducing hot flash discomfort | |
EP3713583A1 (en) | Methods and compositions for treatment of skin | |
JP2002506821A (en) | How to treat skin irritation | |
US20040228908A1 (en) | Topical composition for transdermal administration | |
KR960010002A (en) | L-carnitine salt and cosmetic composition and pharmaceutical composition for treating skin disease containing same | |
US20040126351A1 (en) | Topical composition having natural skin anti-irritant ingredient and method of use | |
US5599546A (en) | Medicinal facial mask | |
JP2002080373A (en) | Preparation for cosmetic and dermatology, containing cyclodextrin in some content for removal of sebum |